Download Full Text (549 KB)
Triple negative breast cancer (TNBC) is one of the rarest types of cancer present today. TNBC lacks the three most common types of receptors: HER2 (HER2-), estrogen receptors (ER-), and progesterone (PR-). This type of breast cancer affects only about 10% of breast cancer patients.Studies have also shown that TNBC primarily affects African-American and Hispanic women. Though many herapeutic drugs have been produced, many of them lack long-term potency. Research has shown that the phytochemical, berberine, possess anticancer properties. Berberine has shown to inhibit a wide range of cancer cell growth in cancer such as: melanoma, prostate, pancreatic,leukemia, and breast. The goal of our research is to synthesize analogs of berberine via Suzuki Coupling reactions. We will place various R groups on the C12 position of berberine. Previous studies have shown that the placing various R groups in the C12 position of berberine enhanced inhibition of breast cancer cells. Herein, we are proposing to synthesize analogs via Suzuki coupling and microwave chemistry. We hypothesize that our analogs of berberine will inhibit the growth of triple negative breast cancer cells in vitro superior to parental compound, berberine.
Xavier University of Louisiana
Nichols Jr, Deeuatrail; Kang, Borui; and Payton-Stewart, Florastina, "Design and Synthesis of Novel Therapeutic Agents for Triple Negative Breast Cancer" (2020). Building Infrastructure Leading to Diversity (BUILD). 5.